Publication | Closed Access

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

Hematological MalignancyMedicineHematologyClinical TrialsVersus CarfilzomibImmune Checkpoint InhibitorPharmacotherapyImmunotherapyOncologyRadiation OncologyRefractory Multiple MyelomaHealth Sciences